Adaptive Biotechnologies Stock

adaptivebiotech.com | Healthcare/Biotech | Founded: 2009 | Funding to Date: $561,367,540

Adaptive is at the forefront of immune-based discoveries, combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. We bring the accuracy and sensitivity of our immunosequencing platform into laboratories around the world to drive groundbreaking research in cancer and other immune-mediated diseases. Adaptive also translates immunosequencing discoveries into clinical diagnostics and therapeutic development to improve patient care.

ENTERPRISE VALUE (based on primary fundings)

Learn more about a potential Adaptive Biotechnologies IPO >>

TEAM

Management Team
  • CHAD ROBINS - Chief Executive Officer, Co-founder
  • HARLAN ROBINS, PHD - Chief Scientific Officer, Co-founder
  • JULIE RUBINSTEIN - President
  • CHAD COHEN - Chief Financial Officer
  • SEAN NOLAN - Chief Technical Officer
  • LANCE BALDO - Chief Medical Officer
Board Members
  • ROBERT HERSHBERG, MD, PhD - Celgene
  • PETER NEUPERT - Operating Partner at Health Evolution Partners
  • ANDRIS ZOLTNERS - Self
  • CHAD ROBINS - Adaptive Biotechnologies
  • MIKE PELLINI, MD -
  • KEVIN CONROY -
  • ERIC DOBMEIER - Adaptive Biotechnologies
  • DAVID GOEL - Matrix Capital Management
  • MICHELLE GRIFFIN - Adaptive Biotechnologies

NEWS

Token Index
Private Growth Index
X